Live tape
Top 8, mentions 7d11,481SPCX2,436 mentions▲ +0.08GOOGL1,990 mentions▲ +0.02META1,795 mentions▲ +0.04TSLA1,707 mentions▲ +0.05NFLX973 mentions▲ +0.03QQQ888 mentions▲ +0.04AMZN849 mentions▲ +0.06NVDA843 mentions▲ +0.06

Equity · Healthcare

ALDX

NASDAQ

Aldeyra Therapeutics (ALDX)

$0.6543 +2.65% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 23, 2026
Price · Chart
63 sessions
$2.0 $0.5 28 Jul 23 Oct

The line runs $1.59 on 28 July through $0.6543 on 23 October, on a scale from $0.5 to $2.0. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 28 Jul – 23 Oct 2026
Market cap $39.5M
Avg volume 62.4K

as of Oct 23, 2026

Aldeyra Therapeutics (ALDX) insider trades

SEC Form 4

ALDX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 3 June 2026.

Date Insider Type Shares Value
03 Jun 2026 Brady Todd C President and CEO Buy 250,000 $418K
19 Mar 2026 DOUGLAS RICHARD Director Buy 70,000 $98K
18 Mar 2026 Alfieri Michael Principal Financial Officer Buy 5,000 $7K

Aldeyra Therapeutics (ALDX) reported financials

SEC EDGAR XBRL SEC EDGAR

Aldeyra Therapeutics reported net income of −$33.8M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$33.8M 31 Dec 2025 fiscal year
Diluted EPS −$0.56 31 Dec 2025 fiscal year
Total assets $47.5M 30 Jun 2026 at period end
Total equity $37.9M 30 Jun 2026 at period end

Aldeyra Therapeutics (ALDX) earnings

SEC EDGAR

Aldeyra Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.09; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.09 —
31 Mar 2026 Q1 2026 −$0.06 —
31 Dec 2025 FY 2025 −$0.56 —
30 Sep 2025 Q3 2025 −$0.13 —
30 Jun 2025 Q2 2025 −$0.16 —
31 Mar 2025 Q1 2025 −$0.17 —
31 Dec 2024 FY 2024 −$0.94 —
30 Sep 2024 Q3 2024 −$0.25 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Aldeyra Therapeutics (ALDX) institutional holders (13F)

SEC Form 13F SEC EDGAR

9 of the 45 institutional funds we track reported a Aldeyra Therapeutics position for the quarter ended 30 Jun 2026 — a combined $19.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Added +32.6% shares 3,751,558 $8.0M
D. E. Shaw & Co. Added +38.2% shares 1,940,338 $4.1M
Marshall Wace Added +1,062.0% shares 1,506,974 $3.2M
Renaissance Technologies Held (±25%) +2.2% shares 882,000 $1.9M
Citadel Advisors Added +42.4% shares 379,144 $808K
Millennium Management Trimmed −63.8% shares 360,350 $768K
Point72 Asset Management New position 154,408 $329K
Man Group New position 152,713 $325K
Two Sigma Investments Trimmed −42.8% shares 127,849 $272K

Aldeyra Therapeutics (ALDX) fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 5,044 shares of Aldeyra Therapeutics failed to deliver (about $7K) — the latest of at least 14 consecutive trading days with recorded fails. The run reaches the start of the window we read, so it may have begun earlier.

Settlement date Shares failed Notional % of shares out
30 Sep 2026 5,044 $7K 0.008%
29 Sep 2026 3,850 $4K 0.006%
28 Sep 2026 3,850 $5K 0.006%
25 Sep 2026 4,178 $5K 0.007%
24 Sep 2026 3,850 $5K 0.006%
23 Sep 2026 3,850 $5K 0.006%
22 Sep 2026 3,850 $5K 0.006%
21 Sep 2026 5,073 $7K 0.008%
18 Sep 2026 7,961 $11K 0.013%
17 Sep 2026 3,850 $5K 0.006%
16 Sep 2026 3,850 $5K 0.006%
15 Sep 2026 3,850 $6K 0.006%
14 Sep 2026 3,850 $5K 0.006%
11 Sep 2026 3,850 $6K 0.006%

Aldeyra Therapeutics (ALDX): frequently asked questions

From live data

Have Aldeyra Therapeutics insiders bought or sold shares recently?

No Aldeyra Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 3 Jun 2026 (SEC Form 4).

How many institutions hold Aldeyra Therapeutics?

9 of the 45 institutional funds we track reported a Aldeyra Therapeutics position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Aldeyra Therapeutics had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Aldeyra Therapeutics is dated 30 Sep 2026, when 5,044 shares failed to deliver.

When did Aldeyra Therapeutics last report earnings?

Aldeyra Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.09; no next date is announced in SEC filings yet.

What exchange is Aldeyra Therapeutics listed on?

Aldeyra Therapeutics trades on NASDAQ under the ticker ALDX.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings